FDMT - Company ID 0001650648
The table below shows 4D Molecular Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $70.37M | $72.49M | $48.55M | $77.16M | $133.53M | $187.54M |
| Short-term investments | $290.96M | $318.40M | $256.51M | $216.07M | $187.91M | $314.35M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $382.96M |
| $405.36M |
| $312.38M |
| $303.29M |
| $332.57M |
| $510.76M |
| Property, plant & equipment | $12.38M | $13.59M | $16.15M | $17.50M | $18.75M | $19.87M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $492.62M | $512.90M | $423.98M | $473.64M | $515.73M | $604.03M |
| Accounts payable | $12.52M | $14.69M | $6.86M | $8.70M | $4.15M | $2.92M |
| Total current liabilities | $47.67M | $43.40M | $37.11M | $34.68M | $26.90M | $29.46M |
| Long-term debt | $19.59M | - | - | - | - | - |
| Total liabilities | $84.96M | $61.07M | $55.00M | $52.75M | $46.01M | $51.08M |
| Retained earnings | -$858.00M | -$785.06M | -$735.70M | -$678.83M | -$624.17M | -$526.52M |
| Total equity | $407.66M | $451.84M | $368.98M | $420.89M | $469.72M | $552.95M |